Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.4610 USD
−67.09 M USD
508.82 M USD
About Blueprint Medicines Corp.
Sector
Industry
CEO
Kathryn Haviland
Website
Founded
2008
FIGI
BBG008ML55T3
Blueprint Medicines develops targeted therapies for cancer and blood disorders, focusing on precision medicine. The company utilizes genetic insights to design treatments tailored to individual patient needs. Their portfolio includes products aimed at specific mutations and conditions, enhancing treatment options for patients with various types of cancer and hematologic diseases. Blueprint Medicines collaborates with healthcare providers to ensure that their therapies are accessible and effectively integrated into patient care. Through ongoing research and development, the company aims to expand its offerings and address unmet medical needs in oncology and hematology.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Blueprint Medicines Corp. stocks are traded under the ticker 2L9.
We've gathered analysts' opinions on Blueprint Medicines Corp. future price: according to them, 2L9 price has a max estimate of 135.00 USD and a min estimate of 129.00 USD. Watch 2L9 chart and read a more detailed Blueprint Medicines Corp. stock forecast: see what analysts think of Blueprint Medicines Corp. and suggest that you do with its stocks.
Yes, you can track Blueprint Medicines Corp. financials in yearly and quarterly reports right on TradingView.
Blueprint Medicines Corp. is going to release the next earnings report on Jul 30, 2025. Keep track of upcoming events with our Earnings Calendar.
2L9 earnings for the last quarter are 0.01 USD per share, whereas the estimation was −0.49 USD resulting in a 102.06% surprise. The estimated earnings for the next quarter are −0.47 USD per share. See more details about Blueprint Medicines Corp. earnings.
Blueprint Medicines Corp. revenue for the last quarter amounts to 149.41 M USD, despite the estimated figure of 155.49 M USD. In the next quarter, revenue is expected to reach 172.75 M USD.
2L9 net income for the last quarter is 496.00 K USD, while the quarter before that showed −49.96 M USD of net income which accounts for 100.99% change. Track more Blueprint Medicines Corp. financial stats to get the full picture.
No, 2L9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 29, 2025, the company has 649 employees. See our rating of the largest employees — is Blueprint Medicines Corp. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Blueprint Medicines Corp. EBITDA is −158.37 M USD, and current EBITDA margin is −38.47%. See more stats in Blueprint Medicines Corp. financial statements.
Like other stocks, 2L9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Blueprint Medicines Corp. stock right from TradingView charts — choose your broker and connect to your account.